WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011156000) USE OF IL-4/IL-13 ANTAGONISTS TO TREAT EOSINOPHILIC DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/156000    International Application No.:    PCT/US2011/001050
Publication Date: 15.12.2011 International Filing Date: 07.06.2011
IPC:
A61K 38/20 (2006.01), C07K 14/54 (2006.01)
Applicants: AEROVANCE, INC. [US/US]; 2929 7th Street Suite 120 Berkeley, CA 94710 (US) (For All Designated States Except US).
OTULANA, Babatunde [US/US]; (US) (For US Only)
Inventors: OTULANA, Babatunde; (US)
Agent: HALIDAY, Emily, M.; Weaver Austin Villeneuve & Sampson LLP P.O. Box 70250 Oakland, CA 94612-0250 (US)
Priority Data:
61/397,174 07.06.2010 US
Title (EN) USE OF IL-4/IL-13 ANTAGONISTS TO TREAT EOSINOPHILIC DISORDERS
(FR) UTILISATION D'ANTAGONISTES DE L'IL-4/IL-13 POUR TRAITER DES TROUBLES ÉOSINOPHILIQUES
Abstract: front page image
(EN)The present invention provides methods for treating eosinophic disorders, including eosinophic asthma, by administering compositions that act as antagonists to IL 4 and IL-13, in particular antisense, RNAi, antibody, and mutant human interleukin-4 (IL-4) antagonists. The invention also provides methods and kits for determining the major allele in certain SNPs in the IL-4 receptor α polypeptide (IL-4RA) as an indication of likely response to IL-4/IL-13 antagonist treatment.
(FR)La présente invention concerne des procédés de traitement de troubles éosinophiliques, notamment de l'asthme éosinophilique, par administration de compositions qui agissent comme antagonistes de l'IL-4 et de l'IL-13, en particulier des antagonistes à base d'oligonucléotides antisens, d'ARNi, d'anticorps, et d'interleukine-4 (IL-4) humaine mutante. L'invention concerne également des procédés et des kits destinés à déterminer l'allèle majeur dans certains SNP du polypeptide α du récepteur de l'interleukine-4 (IL-4RA) comme une indication d'une réponse probable à un traitement avec un antagoniste de l'IL-4/IL-13.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)